London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...
The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.
US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...
Zacks.com on MSN12h
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & MoreIt was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback